TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24236569

Group type: EXPERIMENTAL
Intervention: Planned baby care education and an education booklet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 22421926

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (land-based or aquatic-based treadmill): 3 sessions·week(‐1), progressing to 500 kcal·session(‐1) for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acute exercise session (70% VO(2)max, 400 kcal energy expenditure)
Number of subjects: 18
Study: 20156151

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drug therapy (IP chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drug therapy
Number of subjects: 0
Study: 18458640

Group type: EXPERIMENTAL
Intervention: IdB 1016 (silybin and soy phosphatidylcholine complex)
Number of subjects: 37
Study: 17163231

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 72
Study: 12668301

Group type: EXPERIMENTAL
Intervention: Dörges universal laryngoscope blade
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh laryngoscope blades size 2-4
Number of subjects: 40
Study: 10723115

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 9364183

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 1000 micrograms twice daily for three months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral prednisone 30 mg/day for ten days after each treatment phase
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 1493986

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (both dosages)
Number of subjects: 62
Study: 2419692

Group type: EXPERIMENTAL
Intervention: Pinacidil 37.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinacidil 37.5 mg + Propranolol 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0
Study: 30522481

Group type: EXPERIMENTAL
Intervention: PPFP and PPIUD training
Number of subjects: 14
Study: 27180341

Group type: EXPERIMENTAL
Intervention: Formula 42 (F42)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24532106

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at STN site
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at GPi site
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 37
Study: 22742717

Group type: EXPERIMENTAL
Intervention: dobutamine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 21
Study: 20394495

Group type: EXPERIMENTAL
Intervention: Combination of azelaic acid 5% and erythromycin 2% gel (AzE)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Erythromycin 2%
Number of subjects: 147

Group type: COMPARATOR
Intervention: Azelaic acid 20%
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 18661887

Group type: EXPERIMENTAL
Intervention: High-protein, high-caloric supplement (3 daily servings)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 50
Study: 15844010

Group type: EXPERIMENTAL
Intervention: Self-paced walking (15-20 min, low intensity)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition (passive sitting)
Number of subjects: 15
Study: 11803323

Group type: EXPERIMENTAL
Intervention: Dopamine (2 mg/kg x min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study: 10528377

Group type: EXPERIMENTAL
Intervention: Cotrel-Dubousset instrumentation (rod rotation)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Colorado instrumentation (translation)
Number of subjects: 70
Study: 8720289

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b and ribavirin
Number of subjects: 20
Study: 2040233

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 6274580

Group type: EXPERIMENTAL
Intervention: Noise exposure (100 dBA) for 10 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noise exposure during non-selective beta-adrenoceptor blockade (propranolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 min of quiet rest at 40 dBA after noise exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: beta 1-selective adrenoceptor blockade (metoprolol)
Number of subjects: 0
Study: 29733230

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 413

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 413
Study: 31350658

Group type: EXPERIMENTAL
Intervention: Observation of fearful faces for 30 seconds
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation of neutral image (white screen) for 30 seconds
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation of any image
Number of subjects: 24
Study: 28297053

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 0
Study: 25683312

Group type: EXPERIMENTAL
Intervention: Perioperative rehabilitation intervention during hospitalization (PG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 25145522

Group type: EXPERIMENTAL
Intervention: Systolic BP <140 mm Hg (group 1)
Number of subjects: 8354

Group type: EXPERIMENTAL
Intervention: Systolic BP 140 to <150 mm Hg (group 2)
Number of subjects: 8354

Group type: EXPERIMENTAL
Intervention: Systolic BP ≥150 mm Hg (group 3)
Number of subjects: 8354
Study: 22211362

Group type: COMPARATOR
Intervention: High dose of cloprostenol (87.5 μg; 1.0 ml; i.m.)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Half dose of cloprostenol (43.75 μg; 0.5 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: One third dose of cloprostenol (26.25 μg; 0.3 ml)
Number of subjects: 48
Study: 19205289

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 5 years
Number of subjects: 51

Group type: COMPARATOR
Intervention: Inhaled budesonide, 800 microg/d during pollen season
Number of subjects: 51
Study: 17765649

Group type: EXPERIMENTAL
Intervention: AFA extract
Number of subjects: 12
Study: 15469451

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 11605103

Group type: EXPERIMENTAL
Intervention: High soya diet (100 mg total isoflavones/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low soya diet (0.5 mg total isoflavones/day)
Number of subjects: 0
Study: 9623031

Group type: EXPERIMENTAL
Intervention: Risperidone, final dose 6 mg
Number of subjects: 120
Study: 8076566

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel applied to the throat for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lidocaine solution administered by gargling for five minutes
Number of subjects: 20
Study: 2692588

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1091183

Group type: EXPERIMENTAL
Intervention: 1 mg of haloperidol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31843007

Group type: EXPERIMENTAL
Intervention: Standard RRT strategy (RRT initiated within 12 hours)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Delayed RRT strategy (RRT initiated only if a potentially severe condition occurs or serum urea concentration reaches 50 mmol/l)
Number of subjects: 270
Study: 26611718

Group type: EXPERIMENTAL
Intervention: 1000 mg/day omega-3 fatty acid from flaxseed oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25839731

Group type: EXPERIMENTAL
Intervention: Unhealthy food brand placement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Joint use of advertising and brand placement
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no brand placement)
Number of subjects: 3
Study: 23948819

Group type: EXPERIMENTAL
Intervention: NWB bi-weekly group exercise class
Number of subjects: 40
Study: 21106663

Group type: EXPERIMENTAL
Intervention: Time-varying abstinence
Number of subjects: 236

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 236
Study: 19336785

Group type: EXPERIMENTAL
Intervention: Routine psychosocial care and selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Routine psychosocial care, selective serotonin reuptake inhibitors (SSRIs), and cognitive-behavioural therapy (CBT)
Number of subjects: 192
Study: 16770244

Group type: EXPERIMENTAL
Intervention: WOFIE group (interruption of immunosuppression for 72 hr)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WOFIE group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 14742989

Group type: EXPERIMENTAL
Intervention: Tacrolimus and sirolimus (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tacrolimus and mycophenolate mofetil (MMF) (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) and sirolimus (Group C)
Number of subjects: 150
Study: 11775133

Group type: EXPERIMENTAL
Intervention: COER-verapamil (180 to 540 mg/day)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: COER-verapamil (in women)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: COER-verapamil (in older patients)
Number of subjects: 398
Study: 9835829

Group type: EXPERIMENTAL
Intervention: Potassium nitrate/PCC dentifrice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo dentifrice without potassium nitrate
Number of subjects: 48
Study: 7986516

Group type: EXPERIMENTAL
Intervention: Subcutaneous verapamil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine-verapamil mixture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 2648230

Group type: EXPERIMENTAL
Intervention: Collagen shields applied post-keratoplasty
Number of subjects: 89
Study: 29703004

Group type: EXPERIMENTAL
Intervention: Rational-emotive stress management intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study: 28237535

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo oil (PO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stratification by membrane n-3 PUFA content
Number of subjects: 20
Study: 25652104

Group type: EXPERIMENTAL
Intervention: 800 mg nebulized magnesium
Number of subjects: 365

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 365
Study: 21353794

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (50 Gy/25 Fs/5 wk)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative radiotherapy (50 Gy/25 Fs/5 wk)
Number of subjects: 100
Study: 21321641

Group type: EXPERIMENTAL
Intervention: Docetaxel plus thiotepa (TXT/TSPA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Docetaxel plus capecitabine (TXT/CAPE)
Number of subjects: 46
Study: 19080649

Group type: EXPERIMENTAL
Intervention: Firebird DES implantation and Tirofiban intravenous injection (10 microg x kg(‐1) within 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) for 36 hours)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Cypher DES implantation and Tirofiban
Number of subjects: 323
Study: 12551672

Group type: EXPERIMENTAL
Intervention: IOLMaster optical instrument (Carl Zeiss)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ultrascan Digital 2000 contact ultrasound A-scan (Alcon)
Number of subjects: 134
Study: 10663020

Group type: EXPERIMENTAL
Intervention: PDWHF (platelet derived wound healing factors)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PDWHF
Number of subjects: 15
Study: 7825541

Group type: EXPERIMENTAL
Intervention: Diet B (21% of total energy intake)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diet A (12% of total energy intake)
Number of subjects: 29
Study: 2208024

Group type: EXPERIMENTAL
Intervention: Intraarterial cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Number of subjects: 109

Group type: COMPARATOR
Intervention: Intravenous cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Number of subjects: 109
Study: 38180

Group type: EXPERIMENTAL
Intervention: Treatment (specifics not provided)
Number of subjects: 0
Study: 31915045

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 31202506

Group type: EXPERIMENTAL
Intervention: 50-mg udenafil BID
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 27115565

Group type: EXPERIMENTAL
Intervention: 9 sessions of one-on-one tele-interpersonal psychotherapy (tele-IPT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 132
Study: 25936684

Group type: EXPERIMENTAL
Intervention: High-dose (71ml) GRE acquisitions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-dose (24ml) GRE scans
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose (71ml) 3D-radial acquisitions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-dose (24ml) 3D-radial acquisitions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All scans
Number of subjects: 10
Study: 24169052

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD), 800 micrograms
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study: 21843696

Group type: EXPERIMENTAL
Intervention: Choice group (various condom types)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Control group (one type of condom)
Number of subjects: 1274
Study: 19927459

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17921131

Group type: EXPERIMENTAL
Intervention: ACE D allele carriers
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: APO E epsilon 4 allele carriers
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: AGTR1 C allele carriers
Number of subjects: 248

Group type: COMPARATOR
Intervention: A allele homozygotes
Number of subjects: 248
Study: 15822550

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aspiration combined with methylprednisolone acetate injection plus wrist immobilization
Number of subjects: 28
Study: 11157319

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 9762674

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Interferon‐beta 1a (IFN‐beta 1a)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CST)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 61
Study: 8160980

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (28 degrees C) in Group H
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normothermia in Group N
Number of subjects: 23

Group type: COMPARATOR
Intervention: Mannitol 0.5 g/kg in Group M
Number of subjects: 23
Study: 29379095

Group type: EXPERIMENTAL
Intervention: Erythromycin (40mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study: 27162089

Group type: EXPERIMENTAL
Intervention: Cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching cabotegravir) every 12 hours for 2 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (single open-label dose)
Number of subjects: 0
Study: 24956384

Group type: EXPERIMENTAL
Intervention: More appropriate prosthesis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Less appropriate prosthesis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adaptation period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midpoint of adaptation period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: End of adaptation period
Number of subjects: 24

Group type: COMPARATOR
Intervention: Initial fitting
Number of subjects: 24
Study: 22688340

Group type: EXPERIMENTAL
Intervention: standard control to range (sCTR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: enhanced control to range (eCTR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CSII (Control)
Number of subjects: 38
Study: 20883926

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Lowest coenzyme Q₁₀ tertile
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Coenzyme Q₁₀
Number of subjects: 1191
Study: 19458395

Group type: EXPERIMENTAL
Intervention: Contact lens electrical stimulation of one eye
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison to normal controls
Number of subjects: 17
Study: 16451856

Group type: EXPERIMENTAL
Intervention: Ozone (0.2 ppm) for 4 hr for 4 consecutive days (4D)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ozone (0.2 ppm) for 4 hr for 1 day (1D)
Number of subjects: 15
Study: 15136379

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg bid)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11299153

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional Course
Number of subjects: 80
Study: 9494320

Group type: EXPERIMENTAL
Intervention: 1,800 cGy whole brain radiation therapy (WBRT) plus intrathecal methotrexate (IT MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal methotrexate (IT MTX) alone
Number of subjects: 0
Study: 8516054

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 3326926

Group type: EXPERIMENTAL
Intervention: LHRH nasal spray (400 micrograms three times a day for 28 days)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Orchiopexy (surgical intervention)
Number of subjects: 237
Study: 31870562

Group type: EXPERIMENTAL
Intervention: Daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control intervention (not specified)
Number of subjects: 111
Study: 29276990

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) plus care as usual
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 62
Study: 27244789

Group type: EXPERIMENTAL
Intervention: Screened group (NBS) - Boys (n = 22)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group - Boys (n = 19)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Screened group (NBS) - Girls (n = 10)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group - Girls (n = 13)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Screened group (NBS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 24917333

Group type: EXPERIMENTAL
Intervention: Cognitive aid provided
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no cognitive aid)
Number of subjects: 64
Study: 22858745

Group type: EXPERIMENTAL
Intervention: 3 mg/kg INK
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6 mg/kg INK
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 9 mg/kg INK
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 21207769

Group type: EXPERIMENTAL
Intervention: Individualized protocol-driven verbal and written education with caregiver present using motivational interviewing techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care: verbal and written education at the time of discharge by the discharge nurse
Number of subjects: 20
Study: 18502003

Group type: EXPERIMENTAL
Intervention: DNA‐C priming (4 mg/ml) given intramuscularly at weeks 0 and 4 plus NYVAC‐C at weeks 20 and 24
Number of subjects: 35

Group type: COMPARATOR
Intervention: NYVAC‐C alone
Number of subjects: 35
Study: 15316827

Group type: EXPERIMENTAL
Intervention: PSteE-milk (2.0 g plant sterols/d)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PSteE-spread (4 g plant sterols/d)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PSteE-yoghurt (1.8 g plant sterols/d)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PStaE-yoghurt (1.7 g plant stanols/d)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of PSteE-milk and PSteE-spread
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 12731428

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with simultaneous embolic protection
Number of subjects: 171

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 171